Catalyst Pharmaceuticals (CPRX) Projected to Post Earnings on Wednesday

Catalyst Pharmaceuticals (NASDAQ:CPRX) will likely be releasing its earnings data after the market closes on Wednesday, February 26th. Analysts expect Catalyst Pharmaceuticals to post earnings of $0.32 per share and revenue of $134.20 million for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX stock opened at $21.25 on Tuesday. Catalyst Pharmaceuticals has a 1 year low of $13.91 and a 1 year high of $24.64. The stock has a market cap of $2.53 billion, a PE ratio of 18.01, a price-to-earnings-growth ratio of 3.31 and a beta of 0.80. The business’s fifty day moving average is $22.25 and its 200-day moving average is $21.39.

Analyst Ratings Changes

Several research firms have recently weighed in on CPRX. HC Wainwright raised their price objective on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, January 10th. Truist Financial raised their price objective on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, November 11th. StockNews.com lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 11th. Robert W. Baird began coverage on Catalyst Pharmaceuticals in a research note on Tuesday, February 4th. They set an “outperform” rating and a $28.00 price objective for the company. Finally, Stephens began coverage on Catalyst Pharmaceuticals in a research note on Monday, November 18th. They set an “overweight” rating and a $35.00 price objective for the company. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Catalyst Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $32.25.

Insider Activity at Catalyst Pharmaceuticals

In other news, Director Molly Harper sold 17,500 shares of the business’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total transaction of $385,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Gary Ingenito sold 12,000 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total value of $272,640.00. Following the sale, the insider now owns 51,391 shares of the company’s stock, valued at approximately $1,167,603.52. This represents a 18.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 79,500 shares of company stock valued at $1,754,140. Corporate insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.